Do analysts rate RGC or TBPH?

Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 14.05%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Theravance Biopharma is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Theravance Biopharma 0 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, RGC or TBPH?

Theravance Biopharma has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Theravance Biopharma $107.46M 8.22 $105.89M $1.01 16.84

Does the media refer more to MBX or TBPH?

In the previous week, MBX Biosciences and MBX Biosciences both had 4 articles in the media. MBX Biosciences' average media sentiment score of 1.09 beat Theravance Biopharma's score of 0.29 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TBPH or ARQT?

In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 4 mentions for Theravance Biopharma. Arcutis Biotherapeutics' average media sentiment score of 1.04 beat Theravance Biopharma's score of 0.29 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GPCR or TBPH?

In the previous week, Structure Therapeutics had 13 more articles in the media than Theravance Biopharma. MarketBeat recorded 17 mentions for Structure Therapeutics and 4 mentions for Theravance Biopharma. Structure Therapeutics' average media sentiment score of 0.68 beat Theravance Biopharma's score of 0.29 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MOR or TBPH?

Theravance Biopharma has a consensus target price of $19.40, suggesting a potential upside of 14.05%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Theravance Biopharma is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Theravance Biopharma 0 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Theravance Biopharma (TBPH) Competitors

$17.01 -0.01 (-0.06%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$17.02 +0.00 (+0.03%)

As of 09/11/2026 07:30 PM Eastern

Compare

TBPH vs. RGC, MBX, ARQT, GPCR, and MOR

Should you buy Theravance Biopharma stock or one of its competitors? Theravance Biopharma's main competitors and comparable companies include Regencell Bioscience (RGC), MBX Biosciences (MBX), Arcutis Biotherapeutics (ARQT), Structure Therapeutics (GPCR), and MorphoSys (MOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Theravance Biopharma compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Regencell Bioscience has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Theravance Biopharma has a net margin of 51.58% compared to Regencell Bioscience's net margin of 0.00%. Regencell Bioscience's return on equity of 0.00% beat Theravance Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Theravance Biopharma	51.58%	-0.77%	-0.46%

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Theravance Biopharma had 3 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Theravance Biopharma and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.87 beat Theravance Biopharma's score of 0.29 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Regencell Bioscience	Very Positive
Theravance Biopharma	Neutral

Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 14.05%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Theravance Biopharma is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Theravance Biopharma has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Theravance Biopharma	$107.46M	8.22	$105.89M	$1.01	16.84

Summary

Theravance Biopharma beats Regencell Bioscience on 8 of the 12 factors compared between the two stocks.

How does Theravance Biopharma compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Theravance Biopharma has a net margin of 51.58% compared to MBX Biosciences' net margin of 0.00%. Theravance Biopharma's return on equity of -0.77% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Theravance Biopharma	51.58%	-0.77%	-0.46%

MBX Biosciences has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

MBX Biosciences currently has a consensus target price of $77.00, suggesting a potential upside of 30.46%. Theravance Biopharma has a consensus target price of $19.40, suggesting a potential upside of 14.05%. Given MBX Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe MBX Biosciences is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Theravance Biopharma has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Theravance Biopharma	$107.46M	8.22	$105.89M	$1.01	16.84

In the previous week, MBX Biosciences and MBX Biosciences both had 4 articles in the media. MBX Biosciences' average media sentiment score of 1.09 beat Theravance Biopharma's score of 0.29 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Theravance Biopharma shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Theravance Biopharma beats MBX Biosciences on 9 of the 15 factors compared between the two stocks.

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Theravance Biopharma (NASDAQ:TBPH) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Theravance Biopharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

Theravance Biopharma has a net margin of 51.58% compared to Arcutis Biotherapeutics' net margin of 6.15%. Arcutis Biotherapeutics' return on equity of 15.05% beat Theravance Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Theravance Biopharma has higher earnings, but lower revenue than Arcutis Biotherapeutics. Theravance Biopharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.22	$105.89M	$1.01	16.84
Arcutis Biotherapeutics	$463.98M	6.47	-$16.14M	$0.21	113.76

99.1% of Theravance Biopharma shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Theravance Biopharma presently has a consensus price target of $19.40, indicating a potential upside of 14.05%. Arcutis Biotherapeutics has a consensus price target of $35.57, indicating a potential upside of 48.90%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 4 mentions for Theravance Biopharma. Arcutis Biotherapeutics' average media sentiment score of 1.04 beat Theravance Biopharma's score of 0.29 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcutis Biotherapeutics beats Theravance Biopharma on 11 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Structure Therapeutics currently has a consensus price target of $110.91, indicating a potential upside of 186.88%. Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 14.05%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Structure Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Theravance Biopharma has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Theravance Biopharma	$107.46M	8.22	$105.89M	$1.01	16.84

Theravance Biopharma has a net margin of 51.58% compared to Structure Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of -0.77% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Structure Therapeutics has a beta of -1.45, meaning that its share price is 245% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

In the previous week, Structure Therapeutics had 13 more articles in the media than Theravance Biopharma. MarketBeat recorded 17 mentions for Structure Therapeutics and 4 mentions for Theravance Biopharma. Structure Therapeutics' average media sentiment score of 0.68 beat Theravance Biopharma's score of 0.29 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Theravance Biopharma beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Theravance Biopharma has a consensus target price of $19.40, suggesting a potential upside of 14.05%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Theravance Biopharma is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Theravance Biopharma has a net margin of 51.58% compared to MorphoSys' net margin of -226.79%. Theravance Biopharma's return on equity of -0.77% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Theravance Biopharma	51.58%	-0.77%	-0.46%

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Theravance Biopharma had 4 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for Theravance Biopharma and 0 mentions for MorphoSys. Theravance Biopharma's average media sentiment score of 0.29 beat MorphoSys' score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Theravance Biopharma	Neutral

Theravance Biopharma has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Theravance Biopharma	$107.46M	8.22	$105.89M	$1.01	16.84

Summary

Theravance Biopharma beats MorphoSys on 12 of the 15 factors compared between the two stocks.

Get Theravance Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TBPH vs. The Competition

Export

Metric	Theravance Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$883.66M	$12.43B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	16.84	799.75	275.24	25.29
Price / Sales	8.22	763.36	655.99	98.94
Price / Cash	N/A	89.25	77.04	51.44
Price / Book	2.90	10.39	10.33	6.20
Net Income	$105.89M	$2.85B	$3.50B	$358.50M
7 Day Performance	-0.41%	-3.61%	-3.32%	-2.35%
1 Month Performance	0.53%	0.86%	-0.41%	-2.77%
1 Year Performance	18.95%	3.47%	19.21%	7.63%

Theravance Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TBPH Theravance Biopharma	3.0131 of 5 stars	$17.01 -0.1%	$19.40 +14.1%	+24.2%	$883.66M	$107.46M	16.84	110	Positive News
RGC Regencell Bioscience	0.4766 of 5 stars	$6.78 -1.6%	N/A	-58.1%	$3.37B	N/A	N/A	10	Positive News Gap Up
MBX MBX Biosciences	2.8573 of 5 stars	$63.34 +2.6%	$77.00 +21.6%	+494.4%	$3.05B	N/A	N/A	N/A	Positive News
ARQT Arcutis Biotherapeutics	3.8752 of 5 stars	$24.26 +1.5%	$35.57 +46.6%	+35.0%	$3.04B	$376.07M	115.31	150	Positive News Analyst Downgrade Insider Trade Gap Down
GPCR Structure Therapeutics	2.6522 of 5 stars	$43.45 -8.2%	$110.91 +155.2%	+85.2%	$3.02B	N/A	N/A	136	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TBPH) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Theravance Biopharma (TBPH) Competitors

TBPH vs. RGC, MBX, ARQT, GPCR, and MOR

How does Theravance Biopharma compare to Regencell Bioscience?

Summary

How does Theravance Biopharma compare to MBX Biosciences?

Summary

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Summary

How does Theravance Biopharma compare to Structure Therapeutics?

Summary

How does Theravance Biopharma compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Theravance Biopharma (TBPH) Competitors

TBPH vs. RGC, MBX, ARQT, GPCR, and MOR

How does Theravance Biopharma compare to Regencell Bioscience?

Which has more risk & volatility, RGC or TBPH?

Is RGC or TBPH more profitable?

Do institutionals & insiders believe in RGC or TBPH?

Does the media refer more to RGC or TBPH?

Do analysts rate RGC or TBPH?

Which has higher valuation & earnings, RGC or TBPH?

Summary

How does Theravance Biopharma compare to MBX Biosciences?

Is MBX or TBPH more profitable?

Which has more risk & volatility, MBX or TBPH?

Do analysts prefer MBX or TBPH?

Which has preferable valuation and earnings, MBX or TBPH?

Does the media refer more to MBX or TBPH?

Do institutionals & insiders hold more shares of MBX or TBPH?

Summary

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Which has more risk & volatility, TBPH or ARQT?

Is TBPH or ARQT more profitable?

Which has preferable earnings & valuation, TBPH or ARQT?

Do institutionals & insiders believe in TBPH or ARQT?

Do analysts rate TBPH or ARQT?

Does the media refer more to TBPH or ARQT?

Summary

How does Theravance Biopharma compare to Structure Therapeutics?

Do insiders and institutionals believe in GPCR or TBPH?

Do analysts recommend GPCR or TBPH?

Which has preferable earnings & valuation, GPCR or TBPH?

Is GPCR or TBPH more profitable?

Which has more volatility & risk, GPCR or TBPH?

Does the media favor GPCR or TBPH?

Summary

How does Theravance Biopharma compare to MorphoSys?

Do analysts rate MOR or TBPH?

Which has more volatility & risk, MOR or TBPH?

Is MOR or TBPH more profitable?

Do institutionals and insiders hold more shares of MOR or TBPH?

Does the media favor MOR or TBPH?

Which has preferable valuation & earnings, MOR or TBPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools